Very helpful fouremm. Thanks.

ORI Share conversion =~ 16.1/238.7 = 6.7% ownership of RVX

CALGARY, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that Vision Leader Limited, a wholly-owned subsidiary of ORI Star Fund LP (“ORI”), has delivered a notice of conversion to convert its entire September 2019 debenture and associated interest, into Resverlogix common shares, which will discharge all security interests associated with the debenture. The US$12 million (approximately CAD$15.8 million) principal amount of the debenture and accrued interest in the amount of approximately US$1.3 million (approximately CAD$1.7 million) will be converted into an aggregate of approximately 16.1 million common shares at a price of CAD$1.08 per share.

ORI Capital a healthcare fund established in 2015.

Key Players

Simone Song is the founder and senior partner of ORI Capital. She serves as investor director on a number of companies that ORI Healthcare Fund has invested, including AffyImmune, Cold Genesys, Enable Injections, Kymab, Pillar Biosciences, TriSalus Medical, etc. Simone was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone received a BA in Economics from Fudan University in China and an MA in Economics from Claremont Graduate School.

Dicky To is a partner of ORI Capital. He joined ORI Capital in April 2019. Dicky has over 25 years of experience in structuring, transaction and tax advisory. He was a partner of RSM Hong Kong and worked with the Hong Kong and Shanghai offices of Arthur Andersen for 10 years. Dicky received a Bachelor of Social Sciences in Economics from the University of Hong Kong and an MA in Training & Human Resources from the University of Technology, Sydney. He is a fellow member of the Association of Chartered Certified Accountants and a member of the Hong Kong Institute of Certified Public Accountants.

Elaine Yang is a Director of ORI Capital. She leads the deal initiation, due diligence and execution process as well as the post investment portfolio management activities. Elaine was a Vice President of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was Assistant Manager with the Audit & Assurance Division of KPMG China. Elaine received a BA in English Literature from Tsinghua University and an MBA from UCLA Anderson School of Management. She is a licensed CPA by the Chinese Institute of Certified Public Accountants.

Vincent Chang is a Senior Associate of ORI Capital. Vincent’s primary responsibilities include conducting due diligence and deal execution as well as the post investment portfolio management activities. Vincent worked with the Investment Banking Division of HSBC Hong Kong from 2015 to 2018. He was an Associate with the Healthcare and M&A teams of HSBC before joining ORI Capital. Vincent received a Bachelor of Applied Science in Biomedical Science from the University of Pennsylvania and a BS in Economics from the Wharton School, University of Pennsylvania, and is a candidate for MS in Biotechnology from Johns Hopkins University.

Note the backgrounds - Goldman Sachs, KPMG, Arthur Anderson 

So now we know that Hepa and ORI have done business together beyond RVX so there are  probably relationships.

They both own significant positions in RVX which if combined approach 50%. (not suggesting they want to combine). Between them they hold 2 of 6 board seats.

Based only on some superficial research I believe that the kind of people at ORI and their talent are driven by success and ROI. In my opinion they are not the kind of people to sit around and watch RVX University while away the months and years in scientific discovery. Just my opinion.

I have no idea what they feel they need to do to get to a point of value creation or ROI but it seems clear that there is little evidence that Don is able to deliver. Hope I’m wrong…and soon.

This science has too much value right now. I think if they found a way to put in a bright biotech CEO with a strong business background it would put RVX on the map and begin to provide clear direction and funding for the many scientific opportunities facing RVX including BoM2.

Just an opinion form a frustrated long. Perhaps ORI will help get us there.

Sort of funny but Don seems like a sardine swimming in an ocean smart sharks   :) .

GLTA

Toinv